{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T08:36:30Z","timestamp":1768725390639,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of California Cancer Research Coordinating Committee","award":["CTR#-18-524770"],"award-info":[{"award-number":["CTR#-18-524770"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Although malignant bowel obstruction (MBO) often is a terminal event, systemic therapies are advocated for select patients to extend survival. This study aimed to evaluate factors associated with receipt of chemotherapy after MBO and to determine whether chemotherapy after MBO is associated with survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study investigated patients 65 years of age or older with metastatic gastrointestinal, gynecologic, or genitourinary cancers who were hospitalized with MBO from 2008 to 2012 using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Fine and Gray models were used to identify factors associated with receipt of chemotherapy accounting for the competing risk of death. Cox models identified factors associated with overall survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 2983 MBO patients, 39% (<jats:italic>n<\/jats:italic>= 1169) were treated with chemotherapy after MBO. No differences in receipt of chemotherapy between the surgical and medical patients were found in the univariable analysis (subdistribution hazard ratio [SHR], 0.96; 95% confidence interval [CI], 0.86\u20131.07;<jats:italic>p<\/jats:italic>= 0.47) or multivariable analysis (SHR, 1.12; 95% CI, 1.00\u20131.26;<jats:italic>p<\/jats:italic>= 0.06). Older age, African American race, medical comorbidities, non-colorectal and non-ovarian cancer diagnoses, sepsis, ascites, and intensive care unit stays were inversely associated with receipt of chemotherapy after MBO (<jats:italic>p<\/jats:italic>&lt; 0.05). Chemotherapy with surgery was associated with longer survival than surgery (adjusted hazard ratio [aHR], 2.97; 95% CI, 2.65\u20133.34;<jats:italic>p<\/jats:italic>&lt; 0.01) or medical management without chemotherapy (aHR, 4.56; 95% CI, 4.04\u20135.14;<jats:italic>p<\/jats:italic>&lt; 0.01). Subgroup analyses of biologically diverse cancers (colorectal, pancreatic, and ovarian) showed similar results, with greater survival related to chemotherapy (<jats:italic>p<\/jats:italic>&lt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Chemotherapy plays an integral role in maximizing oncologic outcome for select patients with MBO. The data from this study are critical to optimizing multimodality care for these complex patients.<\/jats:p><\/jats:sec>","DOI":"10.1245\/s10434-021-09831-0","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T20:06:15Z","timestamp":1617825975000},"page":"7555-7563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Chemotherapy After Diagnosis of Malignant Bowel Obstruction is Associated with Superior Survival for Medicare Patients with Advanced Malignancy"],"prefix":"10.1245","volume":"28","author":[{"given":"Sarah B.","family":"Bateni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia A.","family":"Gingrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda R.","family":"Kirane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candice A. M.","family":"Sauder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sepideh","family":"Gholami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Bold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick J.","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-5418","authenticated-orcid":false,"given":"Robert J.","family":"Canter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"key":"9831_CR1","first-page":"CD002764","volume":"1","author":"SE Cousins","year":"2016","unstructured":"Cousins SE, Tempest E, Feuer DJ. Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2016;1:CD002764.","journal-title":"Cochrane Database Syst Rev"},{"key":"9831_CR2","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jpainsymman.2010.05.007","volume":"41","author":"A Chakraborty","year":"2011","unstructured":"Chakraborty A, Selby D, Gardiner K, Myers J, Moravan V, Wright F. Malignant bowel obstruction: natural history of a heterogeneous patient population followed prospectively over two years. J Pain Symptom Manag. 2011;41:412\u201320.","journal-title":"J Pain Symptom Manag"},{"key":"9831_CR3","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1097\/SLA.0000000000002164","volume":"267","author":"EJ Lilley","year":"2017","unstructured":"Lilley EJ, Scott JW, Goldberg JE, et al. Survival, healthcare utilization, and end-of-life care among older adults with malignancy-associated bowel obstruction: comparative study of surgery, venting gastrostomy, or medical management. Ann Surg. 2017;267:692\u201399.","journal-title":"Ann Surg"},{"key":"9831_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ygyno.2012.12.028","volume":"129","author":"SJ Mooney","year":"2013","unstructured":"Mooney SJ, Winner M, Hershman DL, et al. Bowel obstruction in elderly ovarian cancer patients: a population-based study. Gynecol Oncol. 2013;129:107\u201312.","journal-title":"Gynecol Oncol"},{"key":"9831_CR5","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1097\/DCR.0b013e318294ed6b","volume":"56","author":"M Winner","year":"2013","unstructured":"Winner M, Mooney SJ, Hershman DL, et al. Management and outcomes of bowel obstruction in patients with stage IV colon cancer: a population-based cohort study. Dis Colon Rectum. 2013;56:834\u201343.","journal-title":"Dis Colon Rectum"},{"issue":"1 Suppl","key":"9831_CR6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jpainsymman.2007.04.005","volume":"34","author":"RS Krouse","year":"2007","unstructured":"Krouse RS. The international conference on malignant bowel obstruction: a meeting of the minds to advance palliative care research. J Pain Symptom Manag. 2007;34(1 Suppl):S1-6.","journal-title":"J Pain Symptom Manag"},{"key":"9831_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jpainsymman.2013.08.022","volume":"48","author":"G Laval","year":"2014","unstructured":"Laval G, Marcelin-Benazech B, Guirimand F, et al. Recommendations for bowel obstruction with peritoneal carcinomatosis. J Pain Symptom Manag. 2014;48:75\u201391.","journal-title":"J Pain Symptom Manag"},{"key":"9831_CR8","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1089\/jpm.2017.0079","volume":"20","author":"EJ Lilley","year":"2017","unstructured":"Lilley EJ, Cooper Z, Schwarze ML, Mosenthal AC. Palliative care in surgery: defining the research priorities. J Palliat Med. 2017;20:702\u20139.","journal-title":"J Palliat Med"},{"key":"9831_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1089\/jpm.2013.0240","volume":"17","author":"B Badgwell","year":"2014","unstructured":"Badgwell B, Krouse R, Klimberg SV, Bruera E. Outcome measures other than morbidity and mortality for patients with incurable cancer and gastrointestinal obstruction. J Palliat Med. 2014;17:18\u201326.","journal-title":"J Palliat Med"},{"key":"9831_CR10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2147\/CMAR.S29297","volume":"4","author":"A Tuca","year":"2012","unstructured":"Tuca A, Guell E, Martinez-Losada E, Codorniu N. Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution. Cancer Manag Res. 2012;4:159\u201369.","journal-title":"Cancer Manag Res"},{"key":"9831_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/jso.25451","volume":"120","author":"RS Krouse","year":"2019","unstructured":"Krouse RS. Malignant bowel obstruction. J Surg Oncol. 2019;120:74\u20137.","journal-title":"J Surg Oncol"},{"key":"9831_CR12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1200\/JOP.2017.022210","volume":"13","author":"AJ Franke","year":"2017","unstructured":"Franke AJ, Iqbal A, Starr JS, Nair RM, George TJ Jr. Management of malignant bowel obstruction associated with GI cancers. J Oncol Pract. 2017;13:426\u201334.","journal-title":"J Oncol Pract"},{"key":"9831_CR13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1245\/s10434-012-2643-5","volume":"20","author":"C Shaw","year":"2013","unstructured":"Shaw C, Bassett RL, Fox PS, et al. Palliative venting gastrostomy in patients with malignant bowel obstruction and ascites. Ann Surg Oncol. 2013;20:497\u2013505.","journal-title":"Ann Surg Oncol"},{"key":"9831_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/0825859719864915","volume":"35","author":"S Thampy","year":"2020","unstructured":"Thampy S, Najran P, Mullan D, Laasch HU. Safety and efficacy of venting gastrostomy in malignant bowel obstruction: a systematic review. J Palliat Care. 2020;35:93\u2013102.","journal-title":"J Palliat Care"},{"key":"9831_CR15","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1001\/jamasurg.2016.5043","volume":"152","author":"JS Abelson","year":"2017","unstructured":"Abelson JS, Yeo HL, Mao J, Milsom JW, Sedrakyan A. Long-term postprocedural outcomes of palliative emergency stenting vs stoma in malignant large-bowel obstruction. JAMA Surg. 2017;152:429\u201335.","journal-title":"JAMA Surg"},{"key":"9831_CR16","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.critrevonc.2011.12.006","volume":"83","author":"S Mercadante","year":"2012","unstructured":"Mercadante S, Porzio G. Octreotide for malignant bowel obstruction: twenty years after. Crit Rev Oncol Hematol. 2012;83:388\u201392.","journal-title":"Crit Rev Oncol Hematol"},{"key":"9831_CR17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1001\/jamasurg.2013.4059","volume":"149","author":"TJ Paul Olson","year":"2014","unstructured":"Paul Olson TJ, Pinkerton C, Brasel KJ, Schwarze ML. Palliative surgery for malignant bowel obstruction from carcinomatosis: a systematic review. JAMA Surg. 2014;149:383\u201392.","journal-title":"JAMA Surg"},{"key":"9831_CR18","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1245\/s10434-012-2662-2","volume":"20","author":"V Francescutti","year":"2013","unstructured":"Francescutti V, Miller A, Satchidanand Y, Alvarez-Perez A, Dunn KB. Management of bowel obstruction in patients with stage IV cancer: predictors of outcome after surgery. Ann Surg Oncol. 2013;20:707\u201314.","journal-title":"Ann Surg Oncol"},{"key":"9831_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1177\/1049909115569047","volume":"33","author":"J Berger","year":"2016","unstructured":"Berger J, Lester P, Rodrigues L. Medical therapy of malignant bowel obstruction with octreotide, dexamethasone, and metoclopramide. Am J Hosp Palliat Care. 2016;33:407\u201310.","journal-title":"Am J Hosp Palliat Care"},{"key":"9831_CR20","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"key":"9831_CR21","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1200\/JCO.2014.59.7633","volume":"33","author":"MG Fakih","year":"2015","unstructured":"Fakih MG. Metastatic colorectal cancer: current state and future directions. J Clin Oncol. 2015;33:1809\u201324.","journal-title":"J Clin Oncol"},{"key":"9831_CR22","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1634\/theoncologist.2014-0032","volume":"19","author":"MM Kirstein","year":"2014","unstructured":"Kirstein MM, Lange A, Prenzler A, Manns MP, Kubicka S, Vogel A. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data. Oncologist. 2014;19:1156\u201368.","journal-title":"Oncologist"},{"key":"9831_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1023\/A:1008243606668","volume":"8","author":"B Glimelius","year":"1997","unstructured":"Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8:163\u20138.","journal-title":"Ann Oncol"},{"key":"9831_CR24","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1245\/s10434-006-9303-6","volume":"14","author":"LK Helyer","year":"2007","unstructured":"Helyer LK, Law CH, Butler M, Last LD, Smith AJ, Wright FC. Surgery as a bridge to palliative chemotherapy in patients with malignant bowel obstruction from colorectal cancer. Ann Surg Oncol. 2007;14:1264\u201371.","journal-title":"Ann Surg Oncol"},{"key":"9831_CR25","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1186\/s12885-018-5108-9","volume":"18","author":"SB Bateni","year":"2018","unstructured":"Bateni SB, Gingrich AA, Stewart SL, Meyers FJ, Bold RJ, Canter RJ. Hospital utilization and disposition among patients with malignant bowel obstruction: a population-based comparison of surgical to medical management. BMC Cancer. 2018;18:1166.","journal-title":"BMC Cancer"},{"key":"9831_CR26","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jss.2015.03.063","volume":"197","author":"SB Bateni","year":"2015","unstructured":"Bateni SB, Meyers FJ, Bold RJ, Canter RJ. Current perioperative outcomes for patients with disseminated cancer. J Surg Res. 2015;197:118\u201325.","journal-title":"J Surg Res"},{"key":"9831_CR27","doi-asserted-by":"publisher","first-page":"e0165315","DOI":"10.1371\/journal.pone.0165315","volume":"11","author":"SB Bateni","year":"2016","unstructured":"Bateni SB, Meyers FJ, Bold RJ, Canter RJ. Increased rates of prolonged length of stay, readmissions, and discharge to care facilities among postoperative patients with disseminated malignancy: implications for clinical practice. PLoS ONE. 2016;11:e0165315.","journal-title":"PLoS ONE"},{"key":"9831_CR28","volume-title":"AJCC Cancer Staging Manual, Seventh Edition","author":"SB Edge","year":"2010","unstructured":"Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual, Seventh Edition. Springer, New York, NY, 2010."},{"key":"9831_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3656-4","volume-title":"AJCC Cancer Staging Manual, Sixth Edition","author":"FL Greene","year":"2002","unstructured":"Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual, Sixth Edition. Springer, New York, NY, 2002."},{"key":"9831_CR30","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1097\/MLR.0000000000000735","volume":"55","author":"BJ Moore","year":"2017","unstructured":"Moore BJ, White S, Washington R, Coenen N, Elixhauser A. Identifying increased risk of readmission and in-hospital mortality using hospital administrative data: the AHRQ Elixhauser Comorbidity Index. Med Care. 2017;55:698\u2013705.","journal-title":"Med Care"},{"key":"9831_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8\u201327.","journal-title":"Med Care"},{"key":"9831_CR32","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130\u20139.","journal-title":"Med Care"},{"key":"9831_CR33","unstructured":"National Cancer Institute. Procedure Codes for SEER-Medicare Analysis. Retrieved 16 April 2019 at https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/procedure_codes.html."},{"issue":"8 Suppl","key":"9831_CR34","first-page":"55","volume":"40","author":"JL Warren","year":"2002","unstructured":"Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40(8 Suppl):55\u201361.","journal-title":"Med Care"},{"issue":"8 Suppl","key":"9831_CR35","first-page":"49","volume":"40","author":"BA Virnig","year":"2002","unstructured":"Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J. Studying radiation therapy using SEER-Medicare-linked data. Med Care. 2002;40(8 Suppl):49\u201354.","journal-title":"Med Care"},{"key":"9831_CR36","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"9831_CR37","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1002\/sim.7501","volume":"36","author":"PC Austin","year":"2017","unstructured":"Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med. 2017;36:4391\u2013400.","journal-title":"Stat Med"},{"key":"9831_CR38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and life-tables. J R Stat Soc. 1972;34:187\u2013220.","journal-title":"J R Stat Soc"},{"key":"9831_CR39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jamcollsurg.2017.04.033","volume":"225","author":"D Pujara","year":"2017","unstructured":"Pujara D, Chiang YJ, Cormier JN, Bruera E, Badgwell B. Selective approach for patients with advanced malignancy and gastrointestinal obstruction. J Am Coll Surg. 2017;225:53\u20139.","journal-title":"J Am Coll Surg"},{"key":"9831_CR40","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1200\/JCO.2007.15.8253","volume":"26","author":"CC Earle","year":"2008","unstructured":"Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol. 2008;26:3860\u20136.","journal-title":"J Clin Oncol"},{"key":"9831_CR41","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1200\/JCO.2005.07.104","volume":"23","author":"E Voogt","year":"2005","unstructured":"Voogt E, van der Heide A, Rietjens JA, et al. Attitudes of patients with incurable cancer toward medical treatment in the last phase of life. J Clin Oncol. 2005;23:2012\u20139.","journal-title":"J Clin Oncol"},{"key":"9831_CR42","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397.","journal-title":"Lancet"},{"key":"9831_CR43","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med"},{"key":"9831_CR44","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381.","journal-title":"N Engl J Med"},{"key":"9831_CR45","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/cam4.587","volume":"5","author":"J Chouhan","year":"2016","unstructured":"Chouhan J, Gupta R, Ensor J, et al. Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction. Cancer Med. 2016;5:239\u201347.","journal-title":"Cancer Med"},{"key":"9831_CR46","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1200\/JCO.2004.06.050","volume":"22","author":"JH Rose","year":"2004","unstructured":"Rose JH, O\u2019Toole EE, Dawson NV, et al. Perspectives, preferences, care practices, and outcomes among older and middle-aged patients with late-stage cancer. J Clin Oncol. 2004;22:4907\u201317.","journal-title":"J Clin Oncol"},{"key":"9831_CR47","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdq778","volume":"22","author":"U Nappa","year":"2011","unstructured":"Nappa U, Lindqvist O, Rasmussen BH, Axelsson B. Palliative chemotherapy during the last month of life. Ann Oncol. 2011;22:2375\u201380.","journal-title":"Ann Oncol"},{"key":"9831_CR48","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.surg.2012.07.009","volume":"152","author":"JC Henry","year":"2012","unstructured":"Henry JC, Pouly S, Sullivan R, et al. A scoring system for the prognosis and treatment of malignant bowel obstruction. Surgery. 2012;152:747\u201356.","journal-title":"Surgery"},{"key":"9831_CR49","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/jso.21559","volume":"101","author":"FC Wright","year":"2010","unstructured":"Wright FC, Chakraborty A, Helyer L, Moravan V, Selby D. Predictors of survival in patients with non-curative stage IV cancer and malignant bowel obstruction. J Surg Oncol. 2010;101:425\u20139.","journal-title":"J Surg Oncol"},{"key":"9831_CR50","doi-asserted-by":"publisher","first-page":"e1066","DOI":"10.1200\/JOP.18.00793","volume":"15","author":"YC Lee","year":"2019","unstructured":"Lee YC, Jivraj N, Wang L, et al. Optimizing the care of malignant bowel obstruction in patients with advanced gynecologic cancer. J Oncol Prac. 2019;15:e1066\u201375.","journal-title":"J Oncol Prac."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-09831-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-021-09831-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-09831-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T20:46:44Z","timestamp":1724791604000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-021-09831-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["9831"],"URL":"https:\/\/doi.org\/10.1245\/s10434-021-09831-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"assertion":[{"value":"16 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}